Figure 1
In vitro biopharmaceutical assessment of cordycepin (mean ± SD). (a) Time-dependent degradation of cordycepin in rat and human plasma (n = 4). (b) Stabilisation effect of pentostatin on cordycepin tested in rat plasma at different concentrations of pentostatin (1 pM – 10 µM) (n = 4). **p < 0.01 compared to control group (without pentostatin). (c) Plasma protein binding results of cordycepin in rat and human plasma presented as fraction unbound (Fub) in plasma (n = 4). (d) Biorelevant solubility of cordycepin tested in fasted state simulated gastric fluid (FaSSGF), fasted state simulated intestinal fluid (FaSSIF) and fed state simulated intestinal fluid (FeSSIF) (n = 4). **p < 0.01. (e) Permeability of cordycepin tested using Caco-2 cells with co-administration of pentostatin at both apical-to-basolateral (A to B) and basolateral-to-apical (B to A) directions (n = 3). (f) Permeation of 3′-deoxyinosine when Caco-2 cells are treated with cordycepin without co-administration of pentostatin. In this case, permeation of cordycepin was not detected (n = 3). (g) Cordycepin concentrations analysed before and after the permeability experiment in the donor chambers (n = 3). **p < 0.01.
